Evaluation of Triclosan coated suture in obstetrical surgery: A prospective randomized controlled study (NCT05330650)

PLoS One. 2022 Dec 15;17(12):e0278939. doi: 10.1371/journal.pone.0278939. eCollection 2022.

Abstract

Objectives: To assess the effectiveness of Triclosan coated suture in reducing surgical site infections (SSIs) rate after caesarian delivery (CD).

Study design: Three hundred eighty patients were randomly assigned to closure with polyglactin non coated suture VICRYL, or with polyglactin coated suture VICRYL Plus after caesarian section. The primary outcome was the rate of SSIs within 30 days after surgery and secondary outcomes were the rate of wound healing complications.

Results: SSI rate was 2.5% in Triclosan group compared to 8.1% with non-coated suture. Use of Triclosan coated suture (TCS) was associated with 69% reduction in SSI rate (p = 0.037; ORa:0.294; 95% CI:0.094-0.921). The use of Triclosan coated suture was associated with statistically lower risk of wound oedema (2.5% vs 10%), (p = 0.019; OR:0.595), dehiscence (3.8% vs 10.6%), (p = 0.023; OR:0.316) and hematoma (p = 0.035; OR:0.423).

Conclusion: Our results confirm the effectiveness of Triclosan coated suture in reducing SSI rate and wound healing disturbances.

Trial registration: Registered at ClinicalTrials.gov / ID (NCT05330650).

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Anti-Infective Agents, Local* / therapeutic use
  • Female
  • Humans
  • Obstetric Surgical Procedures
  • Polyglactin 910
  • Pregnancy
  • Prospective Studies
  • Surgical Wound Infection / prevention & control
  • Sutures
  • Triclosan* / therapeutic use

Substances

  • Triclosan
  • Polyglactin 910
  • Anti-Infective Agents, Local

Associated data

  • ClinicalTrials.gov/NCT05330650
  • figshare/10.6084/m9.figshare.21330624

Grants and funding

The authors received no specific funding for this work.